(Total Views: 413)
Posted On: 09/30/2025 5:55:35 PM
Post# of 157576
Pending Publications: the safety data on 1.6k patients, AND that last two submitted, esp the last one...I mean, "inflammation" full stop? Finally an actual safe anti-inflammatory for all those conditions on ohm's list-- it's being ticked off faster than I'd imagined!
Pending Publications
Our top publication priority remains a comprehensive TNBC manuscript that includes the clinical and PD-L1 data presented at ESMO,
as well as recent laboratory data generated by Dr. Richard Pestell that appears to reinforce our belief in leronlimab as a paradigm shift
in solid tumor oncology. The initial draft of the manuscript will be ready for internal review in the coming weeks.
The Company has also prepared a case report of a patient with mTNBC whose cancer had spread to both brain and lungs, but who is
alive today without evidence of disease, almost 5 years after receiving fourth-line treatment with leronlimab plus atezolizumab. That
manuscript will be submitted for peer review shortly.
The company is also preparing a safety manuscript summarizing the safety data in almost 1,600 patients who have now been treated
with leronlimab in CytoDyn-sponsored studies.
The company’s manuscript describing the results of CytoDyn’s prior study in patients with Metabolic Dysfunction-Associated
Steatohepatitis was recently accepted for publication.
Finally, we have recently submitted two additional manuscripts for peer-review, including:
● A manuscript of a preclinical study of CRC performed at the Cleveland Clinic, which demonstrated a significant reduction in
lung metastasis in mice treated with leronlimab.
● A manuscript summarizing results from SMC Laboratories detailing the effects of leronlimab on liver fibrosis, inflammation,
and fat.
Pending Publications
Our top publication priority remains a comprehensive TNBC manuscript that includes the clinical and PD-L1 data presented at ESMO,
as well as recent laboratory data generated by Dr. Richard Pestell that appears to reinforce our belief in leronlimab as a paradigm shift
in solid tumor oncology. The initial draft of the manuscript will be ready for internal review in the coming weeks.
The Company has also prepared a case report of a patient with mTNBC whose cancer had spread to both brain and lungs, but who is
alive today without evidence of disease, almost 5 years after receiving fourth-line treatment with leronlimab plus atezolizumab. That
manuscript will be submitted for peer review shortly.
The company is also preparing a safety manuscript summarizing the safety data in almost 1,600 patients who have now been treated
with leronlimab in CytoDyn-sponsored studies.
The company’s manuscript describing the results of CytoDyn’s prior study in patients with Metabolic Dysfunction-Associated
Steatohepatitis was recently accepted for publication.
Finally, we have recently submitted two additional manuscripts for peer-review, including:
● A manuscript of a preclinical study of CRC performed at the Cleveland Clinic, which demonstrated a significant reduction in
lung metastasis in mice treated with leronlimab.
● A manuscript summarizing results from SMC Laboratories detailing the effects of leronlimab on liver fibrosis, inflammation,
and fat.
(6)
(0)
